Jacoline E C Bromberg, Samar Issa, Bronno van der Holt, Matthijs van der Meulen, Linda Dirven, Monique C Minnema, Tatjana Seute, Marc Durian, Gavin Cull, Marjolein W M van der Poel, Wendy B C Stevens, Josee M Zijlstra, Dieta Brandsma, Marcel Nijland, Kylie D Mason, Aart Beeker, Martine C J Abrahamse-Testroote, Martin J van den Bent, Daphne de Jong, Jeanette K Doorduijn
BACKGROUND: Studies on the efficacy of rituximab in Primary CNS Lymphoma (PCNSL) reported conflicting results. Our international randomized phase III study showed that the addition of rituximab to high-dose methotrexate, BCNU, teniposide and prednisolone (MBVP) in PCNSL was not efficacious on the short-term. Here we present long-term results after a median follow-up of 82.3 months. METHODS: 199 eligible newly-diagnosed, non-immunocompromised patients with PCNSL aged 18-70 years with WHO performance status 0-3 were randomized between treatment with MBVP chemotherapy with or without rituximab, followed by high-dose cytarabine consolidation in responding patients, and reduced-dose WBRT in patients aged ≤60 years...
December 1, 2023: Neuro-oncology